Healthcare ETFs are hitting 52-week highs as earnings improve, dealmaking accelerates, FDA approvals stay strong and investors seek defensive growth.
Zacks
More News
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Smart Beta ETF report for XPH
Zacks
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Sector ETF report for XPH
Zacks
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights
H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.
Stocktwits
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
Stocktwits
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?
Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.
Stocktwits
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Smart Beta ETF report for XPH
Zacks
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Sector ETF report for XPH
Zacks
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
Smart Beta ETF report for XPH
Zacks
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?